Welcome to our dedicated page for Aspire Biopharma Holdings news (Ticker: ASBP), a resource for investors and traders seeking the latest updates and insights on Aspire Biopharma Holdings stock.
Aspire Biopharma Holdings, Inc. (Nasdaq: ASBP) is a biotechnology and biopharmaceutical company centered on a patent-pending sublingual delivery platform for drugs and supplements. The ASBP news feed on Stock Titan aggregates coverage of the company’s clinical, regulatory, commercial and capital markets developments, giving readers a focused view of how Aspire’s strategy is progressing over time.
Company press releases describe a lead program in fast-acting, high-dose sublingual aspirin (OTASA) for the emergency treatment of suspected acute myocardial infarction, supported by pilot clinical data and FDA pre‑IND feedback under a 505(b)(2) pathway. News items also cover Aspire’s broader pipeline plans, which include reformulating approved drugs such as erectile dysfunction medications and semaglutide using its sublingual technology.
Beyond pharmaceuticals, Aspire Biopharma reports commercial activities around BUZZ BOMB™, a proprietary sublingual caffeine supplement marketed through its Buzz Bomb Caffeine Company LC subsidiary. News updates highlight product launches, manufacturing scale-up, e‑commerce initiatives, sampling campaigns and brand partnerships with high‑profile endurance athletes.
Investors following ASBP news can also track key corporate events disclosed by the company, such as Nasdaq listing compliance matters, reverse stock split decisions, patent filings, additions to the scientific team and participation in industry conferences like CPHI Frankfurt and virtual equity events. Together, these updates offer insight into Aspire Biopharma’s efforts to advance its sublingual platform, secure partnerships, expand consumer offerings and manage its public listing and financing arrangements. Bookmark this page to review new ASBP headlines, official announcements and related market commentary in one place.
Aspire Biopharma (NASDAQ:ASBP) closed the second and final tranche of a private placement, issuing an aggregate of 26,250 Series A convertible preferred shares for total gross proceeds of $21.0 million, before fees.
The company secured a commitment letter for a senior secured credit facility of up to $22.5 million to finance a proposed $30.0 million cash acquisition of Dura Control Systems (DCS), which reported $200M+ revenue and $20M adjusted EBITDA for FY2025 (unaudited). Aspire said stockholders' equity now exceeds the Nasdaq $2.5M listing minimum and that the DCS purchase is not expected to require new equity.
Aspire Biopharma (NASDAQ:ASBP) subsidiary Buzz Bomb Caffeine Company announced that elite ultramarathoner Ashley Paulson will attempt the female world record for the fastest 100-mile treadmill run at the Boston Marathon Expo on April 18, 2026 at the Hynes Convention Center.
Paulson previously set the 100-mile road world record on February 20, 2026 with a time of 12:19:34 and will aim to beat the treadmill mark of 14:15:08. The event will be live and open to spectators, showcasing Buzz Bomb products.
Aspire Biopharma (NASDAQ:ASBP) signed a Letter of Intent on April 16, 2026 to acquire Dura Driver Control Systems (DCS), a global automotive supplier with 100+ year leadership experience. The proposed acquisition would be for $30 million cash, subject to due diligence and a U.S. GAAP audit.
DCS reported $200M+ revenue and $20M+ adjusted EBITDA for FY2025 (unaudited), holds 310 patents across 275 parts, and serves 150+ vehicle platforms. Management additions from Lakewood & Company add collective industry expertise.
Aspire Biopharma (Nasdaq:ASBP) subsidiary Buzz Bomb Caffeine Company has signed a sales and marketing brokerage agreement with Interwest Brokerage to expand BUZZ BOMB™ retail distribution across Utah, Idaho, and Montana.
The partnership assigns Interwest to lead sales, marketing, and distribution in grocery, convenience, and alternate channels to increase shelf presence and product velocity.
Aspire Biopharma (Nasdaq:ASBP) subsidiary Buzz Bomb Caffeine Company entered an agreement with TruLife Distribution on March 19, 2026, to manage national sales, distribution, and merchandising of BUZZ BOMB™.
The partnership targets natural, organic, specialty, and mass-merchandiser channels to expand retail footprint for the single‑serve 50mg dry‑powder caffeine stick packs.
Aspire Biopharma (Nasdaq:ASBP) announced on March 17, 2026 that subsidiary Buzz Bomb Caffeine Company appointed John Choe as Western Sales Director. Choe is described as a 25-year industry veteran with prior roles at Yerbaé (2016–2025) and a reported 70% sales increase.
The announcement highlights Choe's experience in retail and beverage distribution, DSD and wholesale relationships, multilingual skills, and his MBA and BS degrees as assets to scale Buzz Bomb's western U.S. sales efforts.
Aspire Biopharma (Nasdaq:ASBP) subsidiary Buzz Bomb Caffeine Company will feature its flagship product BUZZ BOMB™ at The Health & Fitness Show, March 16-18, 2026 in San Diego.
BUZZ BOMB™ is a 50mg single-serving dry powder stick pack designed to be sprinkled under the tongue for rapid caffeine absorption, portable dosing, and natural flavors with organic, non-GMO caffeine.
Aspire Biopharma (Nasdaq: ASBP) subsidiary Buzz Bomb Caffeine Company is launching a new BUZZ BOMB Convenience Store Pack, a six-count "Fruit Blast" offering with two each of Tropical Fruit, Mixed Berry, and Peach Mango.
Each single-serving stick contains 50mg fast-acting dry powder caffeine delivered under the tongue; rollout begins in select convenience stores starting in May.
Aspire Biopharma (Nasdaq:ASBP) announced a strategic partnership with Microsize to develop a patent-pending, rapid-delivery sublingual alprazolam powder intended to bypass the digestive tract for faster anxiety relief.
Aspire plans a Phase 1 clinical trial in mid-2026, engaged Pace for formulation and stability work, and cites >15.8 million U.S. prescriptions in 2023 and a projected global alprazolam powder market of $55.84 billion by 2032.
Aspire Biopharma (Nasdaq:ASBP) reported a major brand boost for its wholly owned Buzz Bomb Caffeine Company after sponsoring elite runner Ashley Paulson at the 2026 Jackpot Ultra Running Festival.
Key points: Buzz Bomb content surpassed 400,000 views in 48 hours, and Paulson set a new women's 100-mile world record of 12:19:34, with the company citing increased online revenue and consumer acquisition.